Related Experiment Video

Updated: Jun 9, 2026

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
09:26

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Published on: July 29, 2011

Immune therapeutic targeting of glioma cancer stem cells

Mustafa Aziz Hatiboglu1, Jun Wei, Adam Sauh Gee Wu

  • 1Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Unit 442, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.

Targeted Oncology
|August 26, 2010
PubMed

Insights

Glioblastoma cancer stem cells (gCSCs) resist treatment and suppress immunity, posing challenges for immunotherapy. This review explores targeting gCSCs and suggests novel solutions for glioblastoma treatment.

Area of Science:

  • Neuro-oncology
  • Cancer Immunology
  • Stem Cell Biology

Background:

  • Glioblastoma multiforme (GBM) is an aggressive brain tumor with poor treatment outcomes.
  • Glioma cancer stem cells (gCSCs) drive GBM's resistance to chemotherapy and radiotherapy.
  • gCSCs possess immunosuppressive properties, hindering effective immunotherapy.

Purpose of the Study:

  • To review the current understanding of gCSC-mediated immunosuppression.
  • To reconcile conflicting research on immune targeting of gCSCs.
  • To propose novel therapeutic strategies for glioblastoma.

Main Methods:

  • Literature review of studies on glioblastoma, gCSCs, and cancer immunology.
  • Analysis of mechanisms by which gCSCs suppress innate and adaptive immunity.
  • Synthesis of findings to identify challenges and opportunities for immunotherapy.

Main Results:

  • gCSCs employ secreted factors and cell-surface interactions to evade immune surveillance.
  • Both innate and adaptive immune responses are significantly impaired by gCSCs.
  • Targeting gCSCs presents a promising but complex therapeutic avenue.

Conclusions:

  • Overcoming gCSC-induced immunosuppression is critical for successful glioblastoma immunotherapy.
  • Novel approaches are needed to effectively target gCSCs within the tumor microenvironment.
  • Reconciling current research may pave the way for innovative treatment strategies.

More Related Videos

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells10:28

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds09:18

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds

Published on: July 16, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...